Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Christoph Lengauer
AddedMar 31, 2024
UpdatedMay 31, 2026
Christoph Lengauer

Christoph Lengauer

Co-Founder, Curie.Bio

CrunchbaseLinkedIn

Christoph Lengauer's Career

Curie.Bio
Curie.Bio

Boston, MA, US

Co-Founder
Hookipa Pharma
Hookipa Pharma

New York City, NY, US

Board Member· Board
Celsius Therapeutics
Celsius Therapeutics

Cambridge, MA, US

Board Member· Board
Presage Biosciences
Presage Biosciences

Seattle, WA, US

Board Member· Board
Thrive Earlier Detection
Thrive Earlier Detection

Cambridge, MA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Christoph Lengauer's Career

Curie.Bio
Curie.Bio
Series B262022Boston, MA, US
Co-Founder

Leadership at Curie.Bio

Zach WeinbergZach WeinbergCo-Founder & CEO
Alexis BorisyAlexis BorisyBoard Member

Similar to Curie.Bio

Bioventure PartnersBioventure PartnersChapel Hill, NC, USAdvisory, InvestmentBioventure PartnersChapel Hill, NC, US

Bioventure Partners: Investing in and advising high-impact, tech-driven life science startups.

4
BiotechonomyBiotechonomyNewton, MA, USBiotechonomyNewton, MA, US

Biotechonomy: A venture capital firm specializing in equity financing and management aid for innovative life science startups.

6
Curi BioCuri BioSeattle, WA, USBiotech, Drug Discoveryest. 2015Curi BioSeattle, WA, US · est. 2015

Curi Bio: Accelerating next-gen medicine discovery through human cells, systems, and data integration.

Series A · $20.4M45
Hookipa Pharma
Hookipa Pharma
Public$284.8M1362011New York City, NY, US
Board Member· Board

Leadership at Hookipa Pharma

Joern AldagJoern AldagCEO
Andreas BergthalerAndreas BergthalerCo-Founder
Katherine CohenKatherine CohenCo-Founder
Rolf M. ZinkernagelRolf M. ZinkernagelCo-Founder
Daniel PinschewerDaniel PinschewerCo-Founder
Jan Van De WinkelJan Van De WinkelBoard Member

Similar to Hookipa Pharma

ImmunomeImmunomeExton, PA, USCancer Therapiesest. 2008ImmunomeExton, PA, US · est. 2008

Immunome, a Philadelphia-based biotech company, develops innovative cancer immunotherapies.

Public · $218.9M48
Novita PharmaceuticalsNovita PharmaceuticalsNew York City, NY, USCancer Drugsest. 2010Novita PharmaceuticalsNew York City, NY, US · est. 2010

Novita Pharmaceuticals: Developing and providing cancer-treatment drugs since 2010, based in New York.

Series A · $8.5M7
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
Celsius Therapeutics
Celsius Therapeutics
Series B$148M722018Cambridge, MA, US
Board Member· Board

Leadership at Celsius Therapeutics

Tariq KassumTariq KassumCEO
Aviv RegevAviv RegevFounder

Similar to Celsius Therapeutics

Cedilla TherapeuticsCedilla TherapeuticsCambridge, MA, USTherapeuticsest. 2018Cedilla TherapeuticsCambridge, MA, US · est. 2018

Cedilla Therapeutics: A Massachusetts-based biotech firm innovating small molecule disease treatments.

Series B · $138.8M45
CellarityCellaritySomerville, MA, USMedicine Developmentest. 2017CellaritySomerville, MA, US · est. 2017

Cellarity, a Flagship Pioneering company, harnesses machine learning for innovative medicine development.

Series C · $294M165
Athos TherapeuticsAthos TherapeuticsTorrance, CA, USTherapeuticsest. 2019Athos TherapeuticsTorrance, CA, US · est. 2019

Athos Therapeutics: Pioneering AI-based precision treatments for autoimmune diseases and cancer.

Series A · $19.3M15
Cogent BiosciencesCogent BiosciencesWaltham, MA, USBiotech, Therapiesest. 2014Cogent BiosciencesWaltham, MA, US · est. 2014

US-based Cogent Biosciences develops biotech solutions for genetically driven diseases.

Public · $692.7M138
Presage Biosciences
Presage Biosciences
Acquired$32.6M02008Seattle, WA, US
Board Member· Board

Leadership at Presage Biosciences

Tachi YamadaTachi YamadaBoard Member
Jim OlsonJim OlsonFounder
Richard KlinghofferRichard KlinghofferCEO
Dave JohnsonDave JohnsonBoard Member

Similar to Presage Biosciences

Blaze BioscienceBlaze BioscienceSeattle, WA, USImaging, Tumor Paintest. 2010Blaze BioscienceSeattle, WA, US · est. 2010

Seattle-based Blaze Bioscience develops tumor paint technology for precise, real-time cancer cell visualization.

Series B · $55.4M38
OncoPrecisionOncoPrecisionNew York City, NY, USCancer Treatmentest. 2020OncoPrecisionNew York City, NY, US · est. 2020

Developing advanced tech for personalized cancer treatment and aiding in transformative therapy creation.

Seed · $4.2M37
SeagenSeagenBothell, WA, USCancer Treatmentsest. 1997SeagenBothell, WA, US · est. 1997

Global biotech innovator developing cancer treatments.

Public · $1.7B3.3k
SEngine Precision MedicineSEngine Precision MedicineSeattle, WA, USCancer Drugsest. 2015SEngine Precision MedicineSeattle, WA, US · est. 2015

SEngine Precision Medicine innovatively engineers next-gen cancer-targeted drugs.

Series A · $21.2M23
Thrive Earlier Detection
Thrive Earlier Detection
Late Stage Private$367M1752019Cambridge, MA, US
Co-Founder

Leadership at Thrive Earlier Detection

Steven J. KafkaSteven J. KafkaBoard Member
Neil ExterNeil ExterBoard Member
Isaac KindeIsaac KindeCo-Founder
Nickolas PapadopoulosNickolas PapadopoulosCo-Founder
Kenneth KinzlerKenneth KinzlerCo-Founder
Bert VogelsteinBert VogelsteinCo-Founder

Similar to Thrive Earlier Detection

Early DetectionEarly DetectionSan Diego, CA, USCancerscreeningest. 2017Early DetectionSan Diego, CA, US · est. 2017

Early Detection, founded in 2017, develops non-invasive, accurate cancer screening tests in San Diego.

Seed · $282k7
GRAILGRAILMenlo Park, CA, USCancer Detectionest. 2016GRAILMenlo Park, CA, US · est. 2016

GRAIL, Inc., a Menlo Park-based biotech firm, specializes in early cancer detection using science and technology.

Public · $2B823
FreenomeFreenomeSouth San Francisco, CA, USCancer Detectionest. 2014FreenomeSouth San Francisco, CA, US · est. 2014

Freenome, a US-based company, is dedicated to providing tools for cancer detection, treatment, and prevention.

Late Stage Private · $1.1B375
Harbinger HealthHarbinger HealthCambridge, MA, USBlood Testsest. 2018Harbinger HealthCambridge, MA, US · est. 2018

Harbinger Health: Pioneering early blood cancer detection through innovative testing.

Series B · $190M77

Christoph Lengauer's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Christoph Lengauer

Frank StegmeierFrank StegmeierBoard Member · KSQ TherapeuticsMichael AgustinMichael AgustinCEO · Weaver LabsDan TangDan TangCEO · Curie LondonErika MilczekErika MilczekFounder · CurieRishi KordeRishi KordeFounder · Curie London